drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An influenza virus–vector therapeutic vaccine engineered to present HPV16 E6/E7 oncoprotein antigens to induce HPV-specific cellular immunity (CD8+ and CD4+ T cells). Administered as an initial intracervical dose followed by intramuscular doses, 3 total over 12 weeks.
nci_thesaurus_concept_id
C200854
nci_thesaurus_definition
A cancer vaccine comprised of a modified influenza viral vector that lacks the C-terminal part of the non-structural gene NS1 (delNS) encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration, modified influenza virus expressing HPV16 E6/E7 FluBHPVE6E7 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. HPV16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.
drug_mesh_term
Papillomavirus Vaccines
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intracervical, Intramuscular
drug_mechanism_of_action
Influenza viral-vector therapeutic vaccine encoding HPV16 E6/E7 (delNS attenuated). Following administration, host cells express E6/E7, which are presented via MHC I/II to activate HPV16-specific CD8+ cytotoxic and CD4+ helper T cells, leading to immune-mediated elimination of E6/E7-expressing infected or neoplastic cervical cells.
drug_name
FluBHPVE6E7
nct_id_drug_ref
NCT05829629